GlassScriptPhysician profile
Sally Burbank
NPI 1265465959
$7,375.90
in general payments reported to CMS, 2019-2025
36 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,726 · 2020: $1,123 · 2021: $2,004 · 2022: $1,389 · 2023: $1,134.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,029 · Education: $105.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,029.20 |
| Education | $105.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $935.98 | 2019-2023 | Rybelsus, Ozempic |
| Lilly USA, LLC | $705.93 | 2019-2023 | Jardiance, Mounjaro, Emgality |
| Abbvie INC. | $684.82 | 2019-2023 | Ubrelvy, Creon, Vraylar |
| Pfizer INC. | $576.75 | 2019-2023 | |
| Janssen Pharmaceuticals, INC | $382.27 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $348.64 | 2019-2022 | |
| Amgen INC. | $307.20 | 2019-2021 | |
| Glaxosmithkline, LLC. | $291.19 | 2019-2023 | Arexvy, Trelegy Ellipta |
| Merck Sharp & Dohme LLC | $277.28 | 2019-2022 | |
| Esperion Therapeutics, INC. | $271.14 | 2020-2023 | Nexletol |
| Allergan, INC. | $261.31 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $255.90 | 2020-2023 | Rexulti |
| Novartis Pharmaceuticals Corporation | $191.88 | 2019-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $189.08 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $188.65 | 2021-2023 |
Show all 36 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sally Burbank listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.